{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:13:49Z","timestamp":1792084429904,"version":"4.4.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"intramural program"},{"name":"CCR"},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.leukres.2018.07.015","type":"journal-article","created":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T19:59:17Z","timestamp":1532030357000},"page":"106-111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in Myeloma"],"prefix":"10.1016","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4209-2260","authenticated-orcid":false,"given":"Dalia A.","family":"Salem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Maric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance M.","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Liewehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8990-158X","authenticated-orcid":false,"given":"David J.","family":"Venzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Kochenderfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryalice","family":"Stetler-Stevenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2018.07.015_bib0005","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2018.07.015_bib0010","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.seminoncol.2016.10.008","article-title":"A look backward and forward in the regulatory and treatment history of multiple myeloma: approval of novel-novel agents, new drug development, and longer patient survival","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.leukres.2018.07.015_bib0015","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx030","article-title":"Annual report to the nation on the Status of cancer, 1975\u20132014, featuring survival","volume":"109","author":"Jemal","year":"2017","journal-title":"JNCI: J. Natl. Cancer Inst."},{"key":"10.1016\/j.leukres.2018.07.015_bib0020","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2018.07.015_bib0025","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1182\/blood-2013-08-519413","article-title":"Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation","volume":"122","author":"Kochenderfer","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.07.015_bib0030","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.leukres.2018.07.015_bib0035","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/nar\/22.7.1147","article-title":"The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed","volume":"22","author":"Laabi","year":"1994","journal-title":"Nucl. Acids Res."},{"key":"10.1016\/j.leukres.2018.07.015_bib0040","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1093\/intimm\/7.7.1093","article-title":"BCMAp: an integral membrane protein in the golgi apparatus of human mature B lymphocytes","volume":"7","author":"Gras","year":"1995","journal-title":"Int. Immunol."},{"key":"10.1016\/j.leukres.2018.07.015_bib0045","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.4049\/jimmunol.165.3.1322","article-title":"TNF receptor family member BCMA (B cell maturation) associates with TNF receptor-associated factor (TRAF) 1, TRAF2, and TRAF3 and activates NF-kappa B, elk-1, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase","volume":"165","author":"Hatzoglou","year":"2000","journal-title":"J. Immunol. (Baltimore, Md : 1950"},{"key":"10.1016\/j.leukres.2018.07.015_bib0050","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1182\/blood-2003-06-2043","article-title":"Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival","volume":"103","author":"Novak","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.07.015_bib0055","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.07.015_bib0060","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple Myeloma and related disorders: a report of the International Myeloma Working Group","volume":"121","author":"Kyle","year":"2003","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2018.07.015_bib0065","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/cyto.b.21249","article-title":"Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition","volume":"90","author":"Stetler-Stevenson","year":"2016","journal-title":"Cytometry Part B-Clin. Cytometry"},{"key":"10.1016\/j.leukres.2018.07.015_bib0070","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/cyto.b.20567","article-title":"Variables affecting the quantitation of CD22 in neoplastic B cells","volume":"80","author":"Jasper","year":"2011","journal-title":"Cytometry B Clin. Cytom."},{"key":"10.1016\/j.leukres.2018.07.015_bib0075","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.leukres.2013.12.007","article-title":"Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases","volume":"38","author":"Tembhare","year":"2014","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2018.07.015_bib0080","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.3109\/10428194.2014.955020","article-title":"Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method","volume":"56","author":"Manasanch","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2018.07.015_bib0085","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/cyto.b.21228","article-title":"Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting","volume":"90","author":"Arroz","year":"2016","journal-title":"Cytometry B Clin. Cytom."},{"key":"10.1016\/j.leukres.2018.07.015_bib0090","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.3324\/haematol.2009.009100","article-title":"Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients","volume":"94","author":"Paiva","year":"2009","journal-title":"Haematol.- Hematol. J."},{"key":"10.1016\/j.leukres.2018.07.015_bib0095","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1182\/blood.V99.5.1853","article-title":"Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome","volume":"99","author":"San Miguel","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.07.015_bib0100","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3324\/haematol.11080","article-title":"Report of the European myeloma network on multiparametric flow cytometry in multiple myeloma and related disorders","volume":"93","author":"Rawstron","year":"2008","journal-title":"Haematol.- Hematol. J."},{"key":"10.1016\/j.leukres.2018.07.015_bib0105","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1046\/j.1365-2141.1999.01685.x","article-title":"High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma","volume":"107","author":"Almeida","year":"1999","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2018.07.015_bib0110","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1080\/10428194.2017.1321746","article-title":"Expression of the IL-6 receptor alpha-chain (CD126) in normal and abnormal plasma cells in monoclonal gammopathy of undetermined significance and smoldering myeloma","volume":"59","author":"Salem","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2018.07.015_bib0115","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/bjh.14145","article-title":"Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma","volume":"174","author":"Lee","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2018.07.015_bib0120","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1182\/blood-2004-11-4463","article-title":"Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor","volume":"105","author":"Bellucci","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.07.015_bib0125","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2018.07.015_bib0130","first-page":"122","article-title":"Evaluation of bcma as a therapeutic target in multiple myeloma using an antibody-drug conjugate","author":"Yong","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.07.015_bib0135","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/cyto.b.20541","article-title":"Variables in the quantification of CD4 in normals and hairy cell leukemia patients","volume":"80B","author":"Wang","year":"2011","journal-title":"Cytometry Part B-Clin. Cytometry"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212618301590?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212618301590?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T20:20:39Z","timestamp":1534796439000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212618301590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":27,"alternative-id":["S0145212618301590"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2018.07.015","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in Myeloma","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2018.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}